Abstract
Currently available anticoagulants have limitations for long-term treatment of venous thromboembolism (VTE). We have evaluated the efficacy and safety of direct oral anticoagulants (DOACs) for extended treatment of VTE. Four randomized controlled trials (RCTs) comparing DOACs (apixaban, rivaroxaban, and dabigatran) with placebo or warfarin for extended treatment of VTE were published. Primary efficacy outcome was recurrent VTE or VTE-related death, and primary safety outcome was major bleeding. DOACs significantly lower the risk of recurrent VTE or VTE-related death compared to placebo/warfarin, as well as all-cause mortality. Risk of major bleeding is not different with DOACs compared to placebo/warfarin. However, DOACs are associated with a significantly higher rate of the composite of major and clinically relevant bleeding compared to placebo. In conclusion, DOACs are effective and safe for the extended treatment of VTE, and may reduce the risk of all-cause mortality.
References
White R (2003) The epidemiology of venous thromboembolism. Circulation 107:I4–I8
Dentali F, Ageno W, Pomero F, Fenoglio L, Squizzato A, Bonzini M (2016) Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy. Thromb Haemost 115:399–405
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149:315–352
Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R et al (2007) The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 92:199–205
Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Warfarin Optimal Duration Italian Trial Investigators et al (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 345:165–169
Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Warfarin Optimal Duration Italian Trial Investigators et al (2003) Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 139:19–25
Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR et al (1999) A comparison of 3 months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340:901–907
Palareti G, Antonucci E, Lip GY, Testa S, Guazzaloca G, Falanga A et al (2016) The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study. Thromb Haemost 115:1101–1108
Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D et al (2013) Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368:709–718
Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, The EINSTEIN Investigators et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510
Agnelli G, Buller HR, Cohen A, for the AMPLIFY-EXT Investigators et al (2013) Apixaban for Extended Treatment of Venous Thromboembolism. N Engl J Med 368:699–708
Weitz JI, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, EINSTEIN CHOICE Investigators et al (2015) Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. Thromb Haemost 114:645–650
Undas A, Brummel-Ziedins KE, Mann KG (2014) Anticoagulant effects of statins and their clinical implications. Thromb Haemost 111:392–400
Andreozzi GM, Bignamini AA, Davì G, Palareti G, Matuška J, Holý M, SURVET Study Investigators et al (2015) Sulodexide for the prevention of recurrent venous thromboembolism: the sulodexide in secondary prevention of recurrent deep vein thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation 132:1891–1897
Ageno W, Samperiz A, Caballero R, Dentali F, Di Micco P, Prandoni P, RIETE investigators et al (2015) Duration of anticoagulation after venous thromboembolism in real world clinical practice. Thromb Res 135:666–672
Poli D, Palareti G (2013) Assessing recurrence risk following acute venous thromboembolism: use of algorithms. Curr Opin Pulm Med. 19:407–412
Riva N, Bellesini M, Di Minno MN, Mumoli N, Pomero F, Franchini M et al (2014) Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study. Thromb Haemost 112:511–521
Sardar P, Chatterjee S, Mukherjee D (2013) Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials. Drugs 73:1171–1182
Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, WARFASA Investigators et al (2012) Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 366:1959–1967
Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, ASPIRE Investigators et al (2012) Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 367:1979–1987
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of human and animal rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Imberti, D., Pomero, F., Benedetti, R. et al. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism. Intern Emerg Med 11, 895–900 (2016). https://doi.org/10.1007/s11739-016-1521-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-016-1521-8